Mesa Laboratories, Inc.

As of June 30, 2026, Mesa Laboratories, Inc. carries a market capitalization of 489.63M, placing it among publicly traded companies globally. Its enterprise value stands at 590.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mesa Laboratories, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Mesa Laboratories, Inc. has 5.60M shares outstanding.

As of June 30, 2026, Mesa Laboratories, Inc. trades at a trailing price-to-earnings ratio of 115.82. The price-to-sales ratio is 2.23, and the price-to-book ratio stands at 2.96.

As of June 30, 2026, Mesa Laboratories, Inc. trades at an EV/EBITDA multiple of 14.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Mesa Laboratories, Inc. trades at an EV/FCF ratio of 11.54, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 590.12M versus a market cap of 489.63M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mesa Laboratories, Inc. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 77.08, indicating elevated leverage, while an interest coverage ratio of 4.19 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Mesa Laboratories, Inc. posted a return on equity (ROE) of 2.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.94, useful for judging operating efficiency across full business cycles. The company generates approximately 302,120.65 in revenue per employee across its workforce of 723.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.23 indicates how many times Mesa Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mesa Laboratories, Inc. recorded 3.99M in income tax expense. That works out to an effective tax rate of 48.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.19M, leaving 4.20M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Mesa Laboratories, Inc.'s stock has gained approximately 70.37% over the past 52 weeks. The 50-day moving average sits at 95.76, while the 200-day moving average is 82.54.

Over the twelve months ended June 30, 2026, Mesa Laboratories, Inc. generated 218.58M in revenue and converted that into 4.20M in net income, yielding earnings per share of 0.75. EBITDA reached 39.77M, while operating income came in at 19.67M.

As of June 30, 2026, Mesa Laboratories, Inc. holds 26.87M in cash and equivalents against 127.36M in total debt, resulting in a net debt position of 98.19M. Total book value stands at 165.22M, with working capital of 39.85M providing operational flexibility.

Mesa Laboratories, Inc. produced 48.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.45M in capital expenditures, free cash flow totaled 46.28M - equivalent to 8.32 per share.

Over the twelve months ended June 30, 2026, Mesa Laboratories, Inc. posted a gross margin of 64.21, reflecting its pricing power and cost economics. The operating margin of 9.00 and net profit margin of 1.92 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Mesa Laboratories, Inc. paid dividends of 0.56 per share. The dividend payout ratio of 73.63 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mesa Laboratories, Inc. shareholders.

As of June 30, 2026, Mesa Laboratories, Inc. has an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.